ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)

ClinicalTrials.gov ID: NCT01791153

Public ClinicalTrials.gov record NCT01791153. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 8:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab in Subjects With Giant Cell Arteritis

Study identification

NCT ID
NCT01791153
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
251 participants

Conditions and interventions

Interventions

  • Corticosteroids Drug
  • Methotrexate Drug
  • Prednisone Drug
  • Prednisone Placebo Drug
  • Tocilizumab Drug
  • Tocilizumab Placebo Drug

Drug

Eligibility (public fields only)

Age range
50 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 21, 2013
Primary completion
Apr 10, 2016
Completion
Jun 3, 2018
Last update posted
Feb 5, 2020

2013 – 2018

United States locations

U.S. sites
14
U.S. states
12
U.S. cities
13
Facility City State ZIP Site status
Univ of Calif., Los Angeles; Rheumatology Los Angeles California 90025
Cedars-Sinai Medical Center Los Angeles California 90048
Rheumatology Assoc. of S. Florida - Clinical Research Center Boca Raton Florida 33486
Sarasota Arthritis Res Center Sarasota Florida 34239
Four Rivers Clinical Research Inc. Paducah Kentucky 42003
Rheumatology Associates Portland Maine 04102
Massachusetts General Hospital Boston Massachusetts 02114
Shores Rheumatology Saint Clair Shores Michigan 48081
Mayo Clinic Rochester Rochester Minnesota 55902
Hospital For Special Surgery; Dept of Medicine - Rheumatology New York New York 10021
Asheville Arthritis & Osteoporosis Center, PA Asheville North Carolina 28803
University of Pennsylvania Philadelphia Pennsylvania 19104
University of Utah; Division of Rheumatology Salt Lake City Utah 84132
Marshfield Clinic Wausau Ctr Wausau Wisconsin 54401

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01791153, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 5, 2020 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01791153 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →